Now Available: Poland Pharmaceuticals & Healthcare Report Q1 2015

Released retail pharmacy and national health insurance reimbursement data supports our earlier assertion of a rebound in Q214 and reinforces our full - year forecast for pharmaceutical sales in Poland. We see unemployment trending downwards and rising household consumption boosting overall GDP growth and feeding into an uptick in healthcare expenditure and pharmaceutical sales over the next five years. Over-the-counter medicines and generics will continue to be the primary drivers of growth, with regulatory hurdles holding back sales of innovative drugs.

Headline Expenditure Projections

* Pharmaceuticals: PLN32.39bn (USD10.25bn) in 2013 to PLN33.58bn (USD10.71bn) in 2014; 3.8% in local currency terms and 4.5% in US dollar terms.
* Healthcare: PLN111.44bn (USD35.27bn) in 2013 to PLN115.60bn (USD36.88bn) in 2014; +3.7% in local currency terms and +4.6% in US dollar terms.

Risk/Reward Index

Poland has a RRI score of 61.5 out of 100, making it the most attractive pharmaceutical market in Central and Eastern Europe.

Full Report Details at
- http://www.fastmr.com/prod/912389_poland_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=301

Key Trends And Developments

October 2014

Polish pharmaceutical distributor Neuca plans to enter the high-margin medical clinics segment to compensate for declining profitability in its core business, reports Reuters, citing CEO Piotr Sucharski. At first, the company plans to buy 20 outpatient clinics for USD9mn and has plans for further spending. The investment in the 20-30 clinics is expected to contribute between PLN20mn (USD6mn) and PLN30mn (USD9mn) to Neuca's consolidated revenue. The medical services business is expected to have double-digit margins, significantly more than drug distribution, according to Sucharski.

Poland-based biotechnology company Biogened has signed a contract worth PLN8mn (USD2.41mn) with Romania-based pharmaceutical company Labormed Pharma to renew the licence to distribute Pridinol in Poland, reports Reuters. Under the terms of the contract, Biogened will also transfer rights to dossier and brands of...

The Poland Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Poland Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Polish pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Poland to test other views - a key input for successful budgeting and strategic business planning in the Polish pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
- Thailand Pharmaceuticals & Healthcare Report Q1 2015
- Kenya Pharmaceuticals & Healthcare Report Q1 2015
- Ukraine Pharmaceuticals & Healthcare Report Q1 2015